Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Madrigal Pharmaceuticals, Inc. - Common Stock (NQ:MDGL)

443.24 -48.25 (-9.82%)
Streaming Delayed Price Updated: 2:56 PM EST, Feb 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Madrigal Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Madrigal Pharmaceuticals: Q4 Earnings Insights ↗
 
Via Benzinga
News headline image
Biotech Stocks Madrigal, Altimmune In A Tizzy As New Weight-Loss Rival Enters The Arena ↗
The results from Boehringer Ingelheim and Zealand Pharma bolstered some biotech stocks. But not all got the same boost. 
Via Investor's Business Daily
News headline image
1 Beaten-Down Stock That Could Soar by 40%, According to Wall Street ↗
The company might have a bright future, but is now the right time to buy shares? 
Via The Motley Fool
News headline image
Analysts see over 50% gains in these 2 mid-cap biotech stocks
The outlook for growth has made biotech one of the hottest investments of late - and Wall Street sees big comeback gains ahead in these two biotechs. 
Via MarketBeat
Topics Artificial Intelligence
News headline image
Viking Therapeutics Charges To A Record High On An Update For Its Eli Lilly-Rivaling Obesity Drug ↗
The company is looking to take on Eli Lilly's tirzepatide as both a shot and a pill for weight loss. 
Via Investor's Business Daily
News headline image
Analyst Ratings for Madrigal Pharmaceuticals ↗
 
Via Benzinga
News headline image
2 Risky Stocks With Massive Potential ↗
Neither is doing well this year. 
Via The Motley Fool
News headline image
1 Beaten-Down Stock That Could Soar by 86%, According to Wall Street ↗
This company is on the brink of a major breakthrough. 
Via The Motley Fool
News headline image
Madrigal Pharmaceuticals Stock Shows Rising Relative Strength ↗
A Relative Strength Rating upgrade for Madrigal Pharmaceuticals shows improving technical performance. 
Via Investor's Business Daily
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
2 Rising Biotechs That Could Become the Next Novo Nordisk ↗
Each of these companies has a big market in its sights. 
Via The Motley Fool
News headline image
2 Stocks That Could Soar This Year: Are They Buys? ↗
They might perform well in 2024, but how will they do beyond that? 
Via The Motley Fool
News headline image
Liver Disease Player 89Bio Downgraded: Analyst Sees Short-Term Uncertainties In Fatty Liver Drug Development ↗
89Bio's journey in the clinical-stage biopharmaceutical space. RBC Capital Markets downgrades with insights on FGF21 drugs, pegozafermin, and 2024 uncertainties. 
Via Benzinga
Madrigal Pharmaceuticals Inc. (NASDAQ: MDGL) is a Leading Gainer in 9/13 Morning Trading
Via Investor Brand Network
News headline image
The Latest Analyst Ratings for Madrigal Pharmaceuticals ↗
 
Via Benzinga
News headline image
3 Stocks That Could Be Monster Winners in 2024 ↗
Don't be surprised if these three stocks take off in the new year. 
Via The Motley Fool
News headline image
Why Comtech Telecommunications Shares Are Trading Lower By Over 16%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
Shares of Comtech Telecommunications Corp. (NASDAQ: CMTL) moved lower during Friday’s session following weak quarterly earnings. 
Via Benzinga
News headline image
These 2 Stocks Could Be About to Soar: Are They Buys? ↗
One thing is for certain -- both of these companies are innovators. 
Via The Motley Fool
News headline image
Got $2,000? 3 Growth Stocks to Buy That Could Double Your Money ↗
These stocks just might have investors seeing double over the next few years. 
Via The Motley Fool
News headline image
Can Weight-Loss Drug Ozempic Tip The Scales For Tema's New Healthcare ETF? ↗
New class of weight-reducing drugs underpin launch of exchange-traded fundTema launches healthcare ETF focused on companies researching and treating cardiovascular disease, obesity and diabetes,... 
Via Benzinga
Topics ETFs
News headline image
Madrigal Pharmaceuticals Stock Clears Benchmark, Hits 80+ RS Rating ↗
Madrigal Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 86. 
Via Investor's Business Daily
News headline image
The 3 Most Undervalued Biotech Stocks to Buy: November 2023 ↗
Given the undervalued biotech industry, these three undervalued biotech stocks to buy are ripe purchase targets for high-potential profits. 
Via InvestorPlace
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Nike, Carnival And 3 Stocks To Watch Heading Into Friday ↗
With U.S. stock futures trading higher this morning on Friday, some of the stocks that may grab investor focus today are as follows: 
Via Benzinga
News headline image
Nike, Carnival, Activision Blizzard, Madrigal Pharmaceuticals, Tesla: Why These 5 Stocks Are On Investors' Radars Today? ↗
U.S. stocks traded higher with the Dow Jones gaining over 110 points on Thursday. The Dow traded up 0.35% to 33,666.34 while the NASDAQ rose 0.83% to 13,201.28. 
Via Benzinga
Topics Stocks
News headline image
Wall Street Thinks Madrigal Pharmaceuticals Could Climb 93%. Here's Why It Could Happen Soon. ↗
It has a good shot at commercializing a drug to treat a common liver disease. 
Via The Motley Fool
News headline image
Investors Eye CymaBay's AFFIRM Study As Regulatory Uncertainties Ease ↗
Thursday, CymaBay Therapeutics Inc (NASDAQ: CBAY) initiated the AFFIRM Phase 3b/4 confirmatory study to evaluate the effect of seladelpar on clinical outcomes in patients with compensated cirrhosis due... 
Via Benzinga
News headline image
Madrigal Pharmaceuticals Surges As Its NASH Treatment Toes The Long-Awaited Finish Line ↗
The company is toeing the finish line with a NASH treatment, an area of medicine marked by failures. 
Via Investor's Business Daily
News headline image
Smucker, FuelCell Energy, Granite Ridge Resources And Other Big Stocks Moving Lower On Monday ↗
U.S. stocks traded higher, with the Dow Jones gaining around 100 points on Monday. Here are some big stocks recording losses in today’s session. IHS Holding Limited (NYSE: IHS) shares fell 15.7% to... 
Via Benzinga
Topics Stocks
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.